C&O Pharmaceutical Technology (Holdings) Limited
http://english.changao.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From C&O Pharmaceutical Technology (Holdings) Limited
Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.
Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.
Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Nanjing Changao Pharmaceutical Science and Technology Co., Limited (“Nanjing R&D”)
- Shanghai Sun-sail Pharmaceutical Science & Technology Co., Limited (“Shanghai Sun-sail”)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice